jueves, 12 de julio de 2018

Cancer Information Highlights, July 11, 2018

Cancer Information Highlights, July 11, 2018

National Cancer Institute

Cancer Information Highlights
From the National Cancer Institute
Updating you about cancer causes, prevention, screening, treatment, coping, and more
New from NCI
Changing Chemotherapy May Help Improve Survival for People with Early Pancreatic Cancer
stage 2 A pancreatic cancerResults from two clinical trials are expected to improve the outlook for people with early-stage pancreatic cancer that can be treated with surgery. Learn about the treatment changes that were tested in these studies.
Can Age Affect Response to Immune Checkpoint Inhibitors?
nurse giving patient an infusionA new study has linked age with how well patients with melanoma responded to treatment with immune checkpoint inhibitors. Experiments in mice suggest that the response pattern may be due to an age-related shift in the kinds of immune cells in tumors.
Video—Immunotherapy: How the Immune System Fights Cancer

Immunotherapy is a type of cancer treatment that helps a patient’s immune system fight cancer. Learn about three types of immunotherapy: nonspecific immune stimulation, T-cell transfer therapy, and immune checkpoint inhibitors.
Do Frequent Follow-Up Tests Benefit Survivors of Colon and Rectal Cancers?
gloved hand holding a vialTwo studies examined the impact of more frequent follow-up testing for cancer recurrence in colorectal cancer survivors. Learn whether frequent testing helped patients in the studies live longer.
Approval Expanded for Venetoclax in Chronic Lymphocytic Leukemia

The Food and Drug Administration (FDA) expanded the approval of venetoclax (Venclexta) for people with chronic lymphocytic leukemia to include those whose cancer has progressed after previous treatment, regardless of whether their cancer cells have changes in the 17p gene.
NExT: Advancing Promising Cancer Therapies from the Lab to Clinical Trials

Learn about the NExT program. NCI operates this program, working with researchers and top scientific experts to advance promising or novel therapies from the earliest stages of research to clinical trials in people.
PDQ Summary Updates
Oral Cavity, Pharyngeal, and Laryngeal Cancer Prevention

As the updated title suggests, our PDQ summary on prevention of oral cavity and oropharyngeal cancers now includes information on laryngeal and pharyngeal cancer.
Drug Information Updates
Bevacizumab for Ovarian Cancer 

We’ve updated our bevacizumab (Avastin) drug information summary to reflect FDA’s expanded approval in ovarian, fallopian tube, and primary peritoneal cancer. The drug is now approved for use in stage III and stage IV disease. The previous approval was limited to disease that recurred after earlier chemotherapy.
Pembrolizumab Use in Cervical Cancer and Non-Hodgkin Lymphoma (NHL)

We've updated our drug information summary on pembrolizumab (Keytruda). The drug was recently approved for use in certain patients whose cervical cancer got worse during or after chemotherapy. The approval was also expanded for use in certain patients with primary mediastinal large B-cell lymphoma (a type of NHL) that did not respond to treatment or relapsed after other treatments.
Also of Interest
Radiation and Checkpoint Inhibitors

This story from the NCI Annual Plan and Budget Proposal FY 2019 describes the promise of research that combines radiation therapy, one of cancer medicine’s oldest tools, with immune checkpoint inhibitors.
Access to Experimental Cancer Drugs

Learn how you might gain access to drugs that have been approved for testing in people but can’t yet be advertised, sold, or prescribed.

Lymphoma is a broad term for cancer that begins in cells of the lymph system. Learn about two main types of lymphoma, treatment options, statistics, and research highlights

No hay comentarios:

Publicar un comentario